1 / 19

Composition and Polymer Coating Study on BMS Stents

This study examines the composition and polymer coating of BMS stents, evaluating their performance and residual polymer presence over different time points. The study also analyzes vessel disease, lesion types, and restenosis rates among DES trials. The procedural outcome and MACE rate after 9 months are also reported.

loper
Download Presentation

Composition and Polymer Coating Study on BMS Stents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 9 th month study P. Buszman1,2, R. Gil3, J. Rzezniczak4, T. Przewlocki5, M. Kosmider6, J. Wojcik7, J. Janczak8, S. Trznadel2, L. Kinasz2, M. Kondys2, M. Krol2, K. Milewski1,2 1. Silesian Medical School, Katowice 2. American Heart of Poland, Ustron 3. Central Hospital of the Ministry of Internal Affairs, Warsaw 4. Department of Cardiology, District Hospital, Poznan 5. Institute of Cardiology, CM, JU, Kraków 6. Department of Cardiology and Cardiac Surgery, Medical School, Lodz 7. Division of Cardiology, Lublin 8. Department of Cardiology, Central Military Hospital, Warsaw

  2. The composition of BMS Others: carbon, copper, phosphorus, sulphur, silicon.

  3. The samples of stents covered with tested polymer and removed from isotonic salt solution at different time points The surface of the stent after 1 week The surface after 8 weeks • Residual polymer left on the stent surface after 8 weeks

  4. QCA: Late Loss

  5. Poznan • Warszawa • Lodz • Lublin • Katowice • Ustron • Krakow Bielsko Biała

  6. Silesian Medical School, Katowice P. Buszman Katowice American Heart of Poland M. Kondys Ustron Central Hospital of the Ministry of Internal Affairs R. Gil Warszawa Department of Cardiology, District Hospital J. Rzezniczak Poznan American Heart of Poland L. Kinasz Bielsko Institute of Cardiology, CM, JU, Kraków T. Przewlocki Krakow Department of Cardiology and Cardiac Surgery M. Kosmider Lodz Division of Cardiology J. Wojcik Lublin Department of Cardiology, Central Military Hospital J. Janczak Warszawa

  7. Vessel disease

  8. Lesion type Lesion location B1 42% 37% LAD 41% RCA B2 39% A 10% others 5% LCx 17% C 9% Direct stenting: n = 74 Predilatation: n = 31 Success rate: 100%

  9. Percent diameter stenosis after 9 months

  10. Patterns of in-stent restenosis (Mehran classification) 10% 10% 15,8% 11,1% Restenosis rate 5,7% 0% Risk of restenosis in relation to type of lesion

  11. Comparison Among DES Trials Late Loss Comparison Among DES TRIALS Binary Restenosis (In Stent)

  12. Comparison Among DES Trials MACE

  13. Excellent procedural outcome with device success 100% • Low MACE rate over 9 months after implantation (2.7%) • Favorable late (9 months) angiographic results: - Binary restenosis 10,0% - Late loss 0.45 mm

More Related